Dosage Forms

Hovione Technology has acquired global rights to a dry powder inhaler for pulmonary drug delivery, the Papillon DPI invented by Dr. Klaus-Dieter Beller.

Patient-centric drug development is becoming more important in the bio/pharma industry.

Pharmaceutical Technology and BioPharm International will present a Keynote Session on Meeting Bioprocessing Manufacturing Capacity Demands on Wednesday, April 3, 2019, during INTERPHEX 2019 at the Javits Center in New York City.

Confidence in the quality systems and scientific competence of the API manufacturing team is essential.

Easier access to information, targeting smaller patient populations, and increased regulatory focus on patient outcomes are driving patient‑centric drug development.

Flexibility and well considered manufacturing approaches could help tablet manufacturers face the increasing pressure resulting from the shifting bio/pharma development landscape.

Market demand and regulatory guidance continues to promote improved medication design.

Modified-release oral dosage forms can offer benefits to both formulation scientists and patients.

Valitacell, Solentim, and Microcoat were awarded EUR 3.5 million (US$4 million) to produce an integrated platform to deposit, culture, profile, and select optimal cells for biologic drug manufacturing.

Researchers at the Georgia Institute of Technology developed a technique for administering contraceptive hormones through ‘pharmaceutical jewelry’.

Catalent announces investment for its Zydis ODT technology, offering increased drug load and taste-masking capabilities.

Janssen’s Spravato (esketamine) gains approval with restricted distribution guidelines.

Hetero Labs recalls losartan potassium tablets due to presence of N-Nitroso-N-methyl-4-aminobutyric acid.

Understanding the API, delivery mechanism, and excipient functionality is essential to solving drug solubility challenges.

Containment valves and smart monitoring can keep employees safe and improve manufacturing efficiency when handling potent APIs, intermediates, and solid-dosage drugs.

Optical coherence tomography can improve quality control and development of coated dosage forms by allowing film thickness to be measured in real time.

C-Bridge Capital will form a new biopharmaceutical company, AffaMed Therapeutics, which will collaborate with Samsung Bioepis to accelerate clinical development and registration of Samsung Bioepis’ next-generation biosimilars in China.

Using a QbD approach in the development and formulation of topical products will enable the drug developer to provide a robust control strategy for manufacturing.

The challenge of achieving sustained delivery of an active ingredient or nutrient can be achieved with extended-release formulations.

Drug developers must understand the complex bioanalytical assays for cell- and gene-therapy drug development programs and ensure that partners have the specialized expertise needed for complex therapeutic classes.

This injection formulation of USP-grade leucovorin calcium is now available in the United States.

This article demonstrates how qualitative physical attributes testing can be used to characterize soft gel capsule rupture/disintegration during rectal administration.

Virpax’s Patch-in-a-Can technology delivers pain medication using a metered-dose spray film.

Drug and adhesive formulation are crucial to the development of microneedle patches for pharmaceutical transdermal delivery systems.

Antibody-based drugs offer new mechanisms of action and greater specificity.

Using training devices may ease patient anxiety about using autoinjectors and prefilled syringes, potentially leading to improved patient adherence.

ADC Biotechnology will invest downstream formulation, fill/finish capabilities, and Lock-Release conjugation technology.

Copley Scientific-a manufacturer and provider of test instrumentations for pharmaceutical dosage forms-has officially opened its newly expanded headquarters in Colwick, United Kingdom.

This paper describes how the concept of acceptance value can be redefined to remove bias and more closely reflect quality targets.

Demand for highly potent APIs continues to rise.